Sökning: onr:"swepub:oai:DiVA.org:uu-361283" >
The Potential for T...
-
Svensson, Elin M.,1985-Uppsala universitet,Institutionen för farmaceutisk biovetenskap,Radboud Univ Nijmegen, Radboud Inst Hlth Sci, Dept Pharm, Med Ctr, Nijmegen, Netherlands
(författare)
The Potential for Treatment Shortening With Higher Rifampicin Doses : Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis
- Artikel/kapitelEngelska2018
Förlag, utgivningsår, omfång ...
-
2018-03-21
-
OXFORD UNIV PRESS INC,2018
-
electronicrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-361283
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-361283URI
-
https://doi.org/10.1093/cid/ciy026DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Background. Tuberculosis remains a huge public health problem and the prolonged treatment duration obstructs effective tuberculosis control. Higher rifampicin doses have been associated with better bactericidal activity, but optimal dosing is uncertain. This analysis aimed to characterize the relationship between rifampicin plasma exposure and treatment response over 6 months in a recent study investigating the potential for treatment shortening with high-dose rifampicin. Methods. Data were analyzed from 336 patients with pulmonary tuberculosis (97 with pharmacokinetic data) treated with rifampicin doses of 10, 20, or 35 mg/kg. The response measure was time to stable sputum culture conversion (TSCC). We derived individual exposure metrics with a previously developed population pharmacokinetic model of rifampicin. TSCC was modeled using a parametric time-to-event approach, and a sequential exposure-response analysis was performed. Results. Higher rifampicin exposures increased the probability of early culture conversion. No maximal limit of the effect was detected within the observed range. The expected proportion of patients with stable culture conversion on liquid medium at week 8 was predicted to increase from 39% (95% confidence interval, 37%-41%) to 55% (49%-61%), with the rifampicin area under the curve increasing from 20 to 175 mg/L.h (representative for 10 and 35 mg/kg, respectively). Other predictors of TSCC were baseline bacterial load, proportion of culture results unavailable, and substitution of ethambutol for either moxifloxacin or SQ109. Conclusions. Increasing rifampicin exposure shortened TSCC, and the effect did not plateau, indicating that doses >35 mg/kg could be yet more effective. Optimizing rifampicin dosage while preventing toxicity is a clinical priority.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Svensson, Robin J.Uppsala universitet,Institutionen för farmaceutisk biovetenskap(Swepub:uu)robsv729
(författare)
-
te Brake, Lindsey H. M.Radboud Univ Nijmegen, Radboud Inst Hlth Sci, Dept Pharm, Med Ctr, Nijmegen, Netherlands
(författare)
-
Boeree, Martin J.Radboud Univ Nijmegen, Radboud Inst Hlth Sci, Dept Lung Dis, Med Ctr, Nijmegen, Netherlands
(författare)
-
Heinrich, NorbertUniv Munich LMU, Med Ctr, Munich, Germany;German Ctr Infect Res DZIF, Munich Partner Site, Munich, Germany
(författare)
-
Konsten, SarahUniv Munich LMU, Med Ctr, Munich, Germany;German Ctr Infect Res DZIF, Munich Partner Site, Munich, Germany
(författare)
-
Churchyard, GavinSouth African Med Res Council, Advancing Treatment & Care TB&HIV, Johannesburg, South Africa;Aurum Inst, Johannesburg, South Africa;Univ Witwatersrand, Sch Publ Hlth, Johannesburg, South Africa
(författare)
-
Dawson, RodneyUniv Cape Town, Lung Inst, Cape Town, South Africa
(författare)
-
Diacon, Andreas H.Univ Stellenbosch, Cape Town, South Africa
(författare)
-
Kibiki, Gibson S.Kilimanjaro Clin Res Inst, Moshi, Tanzania
(författare)
-
Minja, Lilian T.Ifakara Hlth Inst, Bagamoyo, Tanzania
(författare)
-
Ntingiya, Nyanda E.NIMR Mbeya Med Res Ctr, Mbeya, Tanzania
(författare)
-
Saone, IanUniv Witwatersrand, Johannesburg, South Africa
(författare)
-
Gillespie, Stephen H.Univ St Andrews, St Andrews, Fife, Scotland
(författare)
-
Hoelscher, MichaelUniv Munich LMU, Med Ctr, Munich, Germany;German Ctr Infect Res DZIF, Munich Partner Site, Munich, Germany
(författare)
-
Phillips, Patrick P. J.UCL, MRC Clin Trials Unit, London, England;Univ Calif San Francisco, Div Pulm & Crit Care Med, San Francisco, CA 94143 USA
(författare)
-
Simonsson, Ulrika S H,ProfessorUppsala universitet,Institutionen för farmaceutisk biovetenskap(Swepub:uu)usv12211
(författare)
-
Aarnoutse, RobRadboud Univ Nijmegen, Radboud Inst Hlth Sci, Dept Pharm, Med Ctr, Nijmegen, Netherlands
(författare)
-
Uppsala universitetInstitutionen för farmaceutisk biovetenskap
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Clinical Infectious Diseases: OXFORD UNIV PRESS INC67:1, s. 34-411058-48381537-6591
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Svensson, Elin M ...
-
Svensson, Robin ...
-
te Brake, Lindse ...
-
Boeree, Martin J ...
-
Heinrich, Norber ...
-
Konsten, Sarah
-
visa fler...
-
Churchyard, Gavi ...
-
Dawson, Rodney
-
Diacon, Andreas ...
-
Kibiki, Gibson S ...
-
Minja, Lilian T.
-
Ntingiya, Nyanda ...
-
Saone, Ian
-
Gillespie, Steph ...
-
Hoelscher, Micha ...
-
Phillips, Patric ...
-
Simonsson, Ulrik ...
-
Aarnoutse, Rob
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Infektionsmedici ...
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Medicinska och f ...
-
och Farmakologi och ...
- Artiklar i publikationen
-
Clinical Infecti ...
- Av lärosätet
-
Uppsala universitet